High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia

Blood

Volumn 103, Issue 8, 2004, Pages 2873-2878

  Kantarjian, Hagop ^a   Talpaz, Moshe ^b   O'Brien, Susan ^b   Garcia Manero, Guillermo ^b   Verstovsek, Srdan ^b   Giles, Francis ^b   Rios, Mary Beth ^b   Shan, Jianqin ^b   Letvak, Laurie ^b   Thomas, Deborah ^b   Faderl, Stefan ^b   Ferrajoli, Alessandra ^b   Cortes, Jorge ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; IMATINIB;

ADULT; AGED; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; BONE PAIN; CANCER SURVIVAL; CARDIOTOXICITY; CHROMOSOME ANALYSIS; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; FATIGUE; FEMALE; FLUID RETENTION; FOLLOW UP; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUTROPENIA; PHILADELPHIA 1 CHROMOSOME; PHILADELPHIA CHROMOSOME POSITIVE CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RASH; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

EID: 11144354274     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-11-3800     Document Type: Article

References (37)

1. Druker BJ, Tamuira S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996;2:561-566.
2. Beran M, Cao X, Estrov Z, et al. Detection of chimeric BCR-ABL genes on bone marrow samples and blood smears in chronic myeloid and acute lymphoblastic leukemia by in situ hybrldization. Blood. 1994;83:1922-1928.
3. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1031-1037.
4. Druker BJ, Lydon NB. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Can Invest. 2000;105:3-7.
5. Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002;346:645-652.
6. Kantarjian HM, Talpaz M, O'Brien S, et al. Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results. Clin Cancer Res. 2002;8:2177-2187.
7. Talpaz M, Silver RT, Druker BJ, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood. 2002;99:1928-1937.
8. Kantarjian HM, O'Brien S, Cortes JE, et al. Treatment of Philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate. Clin Cancer Res. 2002;8:2167-2176.
9. Sawyers CL, Hochhaus A, Feldman E, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood. 2002;99:3530-3539.
10. Kantarjian HM, Cortes J, O'Brien S, et al. Imatinib mesylete (STI571) therapy tor Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood. 2002;99:3547-3553.
11. Kantarjian HM, Cortes JE, O'Brien S, et al. Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses. Blood. 2003;101:97-100.
12. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994-1004.
13. Mahon F, Delbrel X, Cony-Makhoul P, et al. Follow-up of complete cytogenetic remission in patients with chronic myeloid leukemia-like syndrome in mice with v-abl and BCR/ABL. J Clin Oncol. 2003;20:214-220.
14. Bonifazi F, de Vivo A, Gianantonio R, et al. Chronic myeloid leukemia and interferon-a: a study of complete cytogenetic responders. Blood. 2001;98:3074-3081.
15. Kantarjian H, O'Brien S, Cortes J, et al. Complete cytogenetic and molecular responses to interferon-a based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis. Cancer. 2003;97:1033-1041.
16. Garcia-Manero G, Faderl S, O'Brien S, Cortes J, Talpaz M, Kantarjian H. Chronic myelogenous leukemia: a review and update of therapeutic strategies. Cancer. 2003;98:437-457.
17. Faderl S, Talpaz M, Estrov Z, Kantarjian HM. Chronic myelogenous leukemia: biology and therapy. Ann Intern Med. 1999;131:207-219.
18. Kantarjian HM, Talpaz M, O'Brien S, et al. Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood. 2003;101:473-475.
19. Weisberg E, Griffin JD. Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines. Blood. 2000;95:3498-3505.
20. Mahon FX, Deininger MW, Schuitheis B, et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood. 2000;96:1070-1079.
21. le Coutre P, Tassi E, Vareila-Garcia M, et al. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood. 2000;95:1758-1766.
22. Hochhaus A. Cytogenatic and molecular mechanisms of resistance to imatinib. Semin Hematol. 2003;40:69-79.
23. Cortes J, Giles F, O'Brien S, et al. Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-a. Blood. 2003;102:83-86.
24. Kantarjian H, Dixon D, Keating MJ, et al. Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer. 1988;61:1441-1446.
25. Kantarjian HM, Keating MJ, Talpaz M, et al. Chronic myelogenous leukemia in blast crisis: analysis of 242 patients. Am J Med. 1987;83:445-454.
26. Kantarjian HM, Smith T, O'Brien S, Beran M, Pierce S, Talpaz M, The Leukemia Service. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. Ann Intern Med. 1995;122:254-261.
27. Kantarjian HM, Talpaz M, Cortes J, et al. Quantitative polymerese chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; Gleevec) in chronic-phase chronic myelogenous leukemia. Clin Cancer Res. 2003;9:160-166.
28. Hochhaus A, Reiter A, Saussele S, et al. Molecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission. Blood. 2000;95:62-66.
29. Paschka P, Muller M, Merx K, et al. Molecular monitering of response to imatinib (Glivec) in CML patients pretreated with interferon-alpha: low levels of residual disease are associated with continuous remission. Leukemia. 2003;17:1687-1694.
30. Hughes T, Kaeda J, Branford S, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2003;349:1423-1432.
31. Kantarjian HM, O'Brien S, Smith TL, et al. Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine. J Clin Oncol. 1999;17:284-292.
32. Guilhot F, Chastang C, Michallet M, et al. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group. N Engl J Med. 1997;337:223-229.
33. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. N Engl J Med. 1994;330:820-825.
34. Medina J, Kantarjian H, Talpaz, et al. Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. Cancer. 2003;98:1905-1911.
35. Hochhaus A, Lahaye T, Kreif S, et al. Interim analysis of imatinib treatment in 300 patients with chronic myelogenous leukemia (CML): evaluation of response and resistence [abstract]. Proceedings ASCO. 2002;21:262a.
36. Cortes J, O'Brien S, Talpaz M, et al. Clinical significance of molecular response in chronic myeloid leukemia (CML) after imatinib mesylate (Gleevec) therapy: low levels of residual disease predict for response duration [abstract]. Blood. 2003;102:416a.
37. Merx K, Muller MC, Kreil S, et al. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha. Leukemia. 2002;16:1579-1583.